MEDISKIN

“Development of novel medical-grade skincare products for oncology patients”

(SEED/0719/0200)

Although current treatments are resulting in higher survival rates and improved quality of life for cancer patients, dermatological toxicities are still a major concern. Skin irritation, hair changes, erythema, skin infections and dry skin are serious conditions that negatively impact patients’ physical, emotional, and social well- being. If left untreated, such side effects often lead to patients’ noncompliance with or delays in receiving the prescribed anticancer treatment, which in turn may negatively affect clinical outcome. Thus, a proactive attitude towards proper management of dermatological toxicities associated with cancer treatment is crucial to the success of the treatment itself. However, available options for skin care management in cancer patients who are undergoing treatment are still quite limited and products created specifically for those patients who may suffer from dermatologic side effects are continuously being sought. The proposed project
brings together a group of highly motivated SME startups and several leading/world-class research and clinical institutions in Cyprus, putting together a multidisciplinary consortium with substantial resources and expertise in biomaterials, cancer medicine, finance and marketing, in order to develop and commercialize novel skincare products that will be able to successfully compete on the international market. RSL Revolutionary Labs Ltd will focus on the development of high-end products based on medical grade collagen specially formulated to alleviate skin issues and promote wound healing. RSL’s formulas will be developed in collaboration with its dermatologist, biomedical scientist and medical oncologist partners to address this unmet need and introduce effective cosmeceutical solutions to improve skin health and quality of life for cancer patients worldwide.

Consortium: RSL Revolutionary Labs Ltd (HO), Promed Bioscience Ltd (PA1), Theramir Ltd (PA2), LINAC-PET SCAN OPCO Ltd (PA3) and Cyprus University of Technology (PA4)

Duration: 2021-2023

Total budget: €498,505

Funding Agency: The Project is co–funded by the European Regional Development Fund and the Republic of Cyprus through the Research & Innovation Foundation.